An Open-label Multi-dose-escalation, Safety and Pharmacokinetic Study of SAR3419 Administered as a Single Agent by Intravenous Infusion Every 3 Weeks in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (NHL)
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Incidence of Dose Limiting Toxicity(ies) at each tested dose level
Study period
Yes
Clinical Sciences & Operations
Study Director
Sanofi
United States: Food and Drug Administration
TED6828
NCT00549185
October 2007
January 2012
Name | Location |
---|---|
Sanofi-Aventis Administrative Office | Bridgewater, New Jersey 08807 |